E
PBYI icon

Ergoteles’s Puma Biotechnology PBYI Stock Holding History

Ergoteles’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,300
Closed -$81.6K – 1640
2022
Q4 		$81.6K Sell
19,300
-103,309
-84% -$356K ﹤0.01% 1244
2022
Q3 		$291K Sell
122,609
-20,491
-14% -$59.8K 0.01% 993
2022
Q2 		$408K Buy
+143,100
New +$356K 0.01% 932

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Ergoteles's PBYI Position: Q1 2023 in Review

Ergoteles sold out of Puma Biotechnology (PBYI) in Q1 2023, closing a stake of 19,300 shares — an estimated $81.6K sold.

Ergoteles first reported a position in PBYI in Q2 2022 and held it in 3 quarters. The position peaked at $408K in Q2 2022. 77 funds tracked by Wall St. Rank hold PBYI as of Q1 2023.

  • Ergoteles reported no remaining Puma Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 19,300 Puma Biotechnology shares in Q1 2023, an estimated $81.6K.
  • Ergoteles first reported a position in Puma Biotechnology in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Puma Biotechnology position peaked at $408K in Q2 2022.
  • 77 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.